Bio Pharma Dive
FEBRUARY 3, 2025
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.
Pharmaceutical Technology
FEBRUARY 3, 2025
Sanofi has received Chinas NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating adults with NDMM.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
FEBRUARY 3, 2025
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.
Pharmaceutical Technology
FEBRUARY 3, 2025
The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
FEBRUARY 3, 2025
China is now a dealmaking hot spot for firms seeking next-generation innovation. What will 2025 hold?
Pharmaceutical Technology
FEBRUARY 3, 2025
The colon cancer BRAFF mutation study is one of the first to be initiated under the FDAs Project FrontRunner.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 3, 2025
L'Oral is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Pharma Times
FEBRUARY 3, 2025
Funding led by new investors FSG and EIC Fund
Pharmaceutical Technology
FEBRUARY 3, 2025
AdvanCells lead candidate ADVC001 is being evaluated in a Phase I/II dose escalation clinical trial.
Pharma Times
FEBRUARY 3, 2025
Positive opinion issued for marketing authorisation extension
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
FEBRUARY 3, 2025
The FDA has granted approval for Celltrion's Avtozma in both IV and SC formulations as Actemra biosimilar for treating several conditions.
pharmaphorum
FEBRUARY 3, 2025
Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?
Pharmaceutical Technology
FEBRUARY 3, 2025
The EC has authorised the use of ViiV Healthcares Vocabria plus Rekambys from J&J for treating adolescents with HIV-1.
Pharmaceutical Commerce
FEBRUARY 3, 2025
The latest news for pharma industry insiders.
Pharmaceutical Technology
FEBRUARY 3, 2025
On World Cancer Day, tackling barriers in equitable care requires not only policy action, but a shift in how cancer is examined.
Pharmaceutical Commerce
FEBRUARY 3, 2025
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, describes the highlights of a recent pharma supply chain security and visibility report that his company released.
Pharmaceutical Technology
FEBRUARY 3, 2025
On World Cancer Day, tackling barriers in equitable cancer care requires not only policy action, but a shift in how cancer is examined.
pharmaphorum
FEBRUARY 3, 2025
Explore the latest trends and insights in the life sciences industry with Part 7 of our industry report. This white paper provides valuable information for professionals in the field.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
CTTI (Clinical Trials Transformation Initiative)
FEBRUARY 3, 2025
Hot Spots for Decentralized Clinical Trials: Reframing Old Challenges The post Hot Spots for Decentralized Clinical Trials: Reframing Old Challenges appeared first on CTTI.
pharmaphorum
FEBRUARY 3, 2025
Explore the intersection of scientific pedigree and collaboration in innovating within the oncology pipeline. Learn how these factors drive advancements in cancer research and treatment.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 3, 2025
As global trade and e-commerce are expected to expand rapidly in 2025, the need for robust traceability and authentication solutions has become critical. Counterfeiting, product diversion, and parallel trade pose serious threats to pharmaceuticals among others resulting in financial losses and eroding consumer trust, stated Manoj Kochar, president of Authentication Solution Providers Association (ASPA).
pharmaphorum
FEBRUARY 3, 2025
It's been reported that the UK government made an offer of 78m in funding for AstraZeneca's abandoned 450 million vaccine facility in Speke
ACRP blog
FEBRUARY 3, 2025
The Association of Clinical Research Professionals (ACRP) is proud to welcome its new class of 2025 Fellows. Recognized with the FACRP designation for their contributions to ACRP and to the clinical trial industry, each member has demonstrated commitment to advancing the profession by sharing his or her experiences and mentoring others in the field.
Drug Patent Watch
FEBRUARY 3, 2025
Breaking Down Barriers in Pediatric Care: The Power of Biosimilars As healthcare professionals, we're constantly on the lookout for innovative solutions that can improve patient outcomes and make a meaningful difference in their lives. One area that's gaining significant attention is the use of biosimilars in pediatric care. But what exactly are biosimilars, and how can they enhance accessibility and affordability for our young patients?
Drug Channels
FEBRUARY 3, 2025
Informa Connect's Access USA March 18-20, 2025, Pre-Event Workshops on March 17 Drug Channels readers save 10%* on their registration with code 25AUSA10 Three events. One roof. The future of patient access. Theres a lot to discuss, and Access USA is ready to deliver: policy updates, PBM reform, commercialization strategies and more! Access USA unites PAP Patient Assistance & Access Programs , Hub and Specialty Pharmacy Models East and Rare Disease Summit : three influential access conferenc
pharmaphorum
FEBRUARY 3, 2025
The future of USAID, the world's largest donor of humanitarian aid, is in doubt as the Trump administration threatens to merge it with the state department
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
FEBRUARY 3, 2025
What implications will these have on the pharma supply chain?
Expert insights. Personalized for you.
297 
Let's personalize your content